The subsidiary of Noveko International Inc., Laboratoire SyMa Inc., manufacturer of the AZURO(TM) products, signs two major agreements with METRO INC. and the Fédération des Caisses Desjardins du Québec



    Issuance of an establishment licence and a DIN by Health Canada,
    authorizing SyMa to sell its products in hospitals and other healthcare
    institutions - and FDA authorization to market its products in the United
    States.

    EKO / TSX Venture Exchange

    MONTREAL, Nov. 21 /CNW Telbec/ - NOVEKO INTERNATIONAL INC. ("Noveko" or
the "Company") announces that its subsidiary Laboratoire SyMa Inc. ("SyMa"),
which specializes in the manufacture of antimicrobial sanitizers (for hands,
feet and surfaces) sold under the Azuro(TM) trademark, has signed two major
agreements: one with METRO INC., a leading food distributor in Canada, and the
other with the Fédération des Caisses Desjardins du Québec. In addition, SyMa
has been issued a Health Canada establishment licence and DIN (drug
identification number) for all its products, more specifically the Azuro
medical (70% alcohol and 0.5% chlorhexidine gluconate) - allowing it to sell
them in healthcare institutions across Canada. It has also received FDA
authorization to market its Azuro(TM) products in the United States.
    "The acquisition of SyMa represents an excellent source of growth,
considering among others the potential of the hospitals market for this type
of product, estimated at some $20 million in Canada and approximately
US$200 million in the U.S.," indicated Alain Bolduc, President and Chief
Operating Officer of Noveko.
    SyMa has entered into an agreement with METRO INC., under which it will
supply its line of Azuro(TM) products to the METRO and METRO Plus supermarkets
as well as the Super C discount supermarkets, representing more than 280
stores operating in Quebec. SyMa has also signed a three-year agreement with
the Fédération des Caisses Desjardins du Québec, whereby it will supply its
line of Azuro(TM) products to the network of Desjardins credit unions and
their service centres, representing more than 1,400 Desjardins branches across
Canada.
    Marc Demers, President of SyMa, said: "I am particularly pleased with the
milestones achieved in obtaining the Health Canada establishment licence and
DIN and the FDA authorization. Our products stand apart for their presentation
and properties, notably the rapid elimination of 99.9% of germs; they are
currently distributed by various drugstore chains, Le Comptoir Wal-Mart,
several hundred Couche-Tard convenience stores and retail outlets in Quebec.
We are hence most satisfied to broaden our client base with two new
prestigious and successful clients such as METRO INC. and the Fédération des
Caisses Desjardins. We are focused on developing our markets in North America,
while expanding our product line and building synergies with Noveko, which is
marketing its antimicrobial face masks and air filters worldwide."

    Amendment to Stock Option Plan
    -------------------------------

    The TSX Venture Exchange approved, on November 20, 2007, the amendment to
the Stock Option Plan of the Corporation adopted by the Board of Directors of
the Corporation increasing the number of Class A Shares that may be issued
following the exercise of options granted or to be granted under the Plan from
8,242,776 to 10,698,780 Class A Shares. As of the hereof, options under which
a total number of 5,925,261 shares are outstanding. This approval is subject
to the approval of the amendment, by the shareholders of the Corporation, at
the Annual General and Special Meeting of the shareholders to be held on
December 12, 2007.

    Profile
    -------

    Noveko International Inc. currently has four subsidiaries: S.A.S. ECM,
Noveko Inc., Laboratoire SyMa Inc. ("SyMa") and Bolduc Leroux Inc. ("BLI").
ECM specializes in the design and marketing of portable real-time ultrasound
scanners for use in veterinary and human medicine. Noveko Inc. develops the
Company's biomedical and environmental business, specifically its patented
antimicrobial filtration technology and derivative products (Noveko(TM)
antimicrobial face masks and air filters). SyMa specializes in the manufacture
of sanitizers, more specifically the antimicrobial products (for hands, feet
and surfaces) sold under the Azuro(TM) trademark. For its part, BLI
specializes in the custom processing and distribution of steel products based
on client specifications and designs. It has also developed and markets a line
of downdraft particle extraction tables for various markets. Operating since
September 2002, the Company was listed on the TSX Venture Exchange on
February 3, 2004.

    The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.




For further information:

For further information: André Leroux, Chairman of the Board and Chief
Executive Officer; Alain Bolduc, President and Chief Operating Officer, Noveko
International Inc., (514) 344-3030, http://www.noveko.com; (450) 585-1117,
http://www.azuro.ca

Organization Profile

Noveko International Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890